Avita Medical improves ReCell Spray-on Skin

Avita Medical (ASX:AVH) has launched a version of its ReCell Spray-on Skin product that no longer requires refrigeration.

The company has started selling the new version in the UK and Europe, but is still preparing a TGA application in Australia.

Upon approval, Avita Medical plans to phase out all sales and manufacturing of the refrigerated version.

Avita Medical CEO Tim Rooney said eliminating the requirement for temperature control will make the product more attractive to clinicians.

“Until now, ReCell has required refrigeration, which often meant it was not immediately on hand in the operating theatre,” he said. “The fact that this product can be stored on the shelf until use is a valuable element in providing a more convenient and attractive product, particularly in situations where time is of critical importance.”

The company managed to remove the refrigeration requirement by replacing an enzyme used in the cell disaggregation process. ReCell uses this process to isolate a patient's skin cells and collect them in suspension for reintroduction to the patient.

The product is designed for applications including the treatment of burns, scars, chronic wounds and vitiligo.

Avita Medical (ASX:AVH) shares were trading 4.17% higher at $0.125 as of around 1.30 pm on Wednesday.